pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Adverse event reports on cancer immunotherapeutic agents and all other drugs by different characteristics from 2013 to 2017 (number, (%))
| Characteristics | Number of ICSRs on cetuximab | Number of ICSRs on all other CITAs | Number of ICSRs on all other drugs | |
|---|---|---|---|---|
| Sex | <0.001 | |||
| Male | 1,409 (66.59) | 13,402 (48.17) | 347,544 (41.55) | |
| Female | 707 (33.41) | 14,423 (51.83) | 507,159 (58.45) | |
| Age group | <0.001 | |||
| 0-19 | 2 (0.09) | 220 (0.79) | 53,492 (6.16) | |
| 20-39 | 101 (4.77) | 2,317 (8.33) | 139,852 (16.12) | |
| 40-64 | 1,236 (58.41) | 16,566 (59.54) | 409,684 (47.21) | |
| Over 65 | 777 (36.72) | 8,722 (31.35) | 264,675 (30.51) | |
| Reporter | <0.001 | |||
| Doctor | 1,089 (51.91) | 15,223 (56.24) | 232,143 (26.75) | |
| Pharmacist | 104 (4.96) | 1,612 (5.96) | 115,178 (13.27) | |
| Nurse | 681 (32.46) | 6,737 (24.89) | 435,659 (50.21) | |
| Other health professionals | 1 (0.05) | 27 (0.10) | 1,329 (0.15) | |
| Consumer | 217 (10.34) | 3,155 (11.66) | 44,611 (5.14) | |
| Others | 6 (0.29) | 313 (1.16) | 17,081 (1.98) | |
| NA |
18 (0.85) | 758 (2.72) | 21,702 (2.50) | |
| Report center | <0.001 | |||
| Regional pharmacovigilance center | 902 (42.63) | 8,894 (31.96) | 649,846 (77.37) | |
| Pharmaceutical company | 1,186 (56.05) | 18,657 (67.05) | 159,712 (19.02) | |
| Clinic | 28 (1.32) | 240 (0.86) | 20,913 (2.49) | |
| Pharmacy | 0 (0) | 33 (0.12) | 1,139 (0.14) | |
| Consumer | 0 (0) | 0 (0) | 6,209 (0.74) | |
| Others | 0 (0) | 1 (0.00) | 2,052 (0.24) | |
| NA |
0 (0) | 0 (0) | 7 (0.00) | |
| Total | 2,116 (100) | 27,825 (100) | 867,703(100) |
*NA: number of missing reports
ICSR, individual case safety report; CITA, cancer immunotherapeutic agent